� 'PliiAPT ih �� � GNAS :::; 1�� ':t '"�� � =�� SYSTEM -si;�-;;db;:·x�-Zh��x� MEMBER OF ••••• ......... .· .•.. •·····--·· . . � IQNET CHINA QUALITY CERTIFICATION CENTRE Section 9, No.188, Nansihuan(the South Fourth Ring Road) Xilu(West Road), Beijing 100070, China http://www.cqc.com.cn A 0082431 20221:f=�&

AVIENT CORPORATION COMPENSATION COMMITTEE CHARTER Membership • The Committee will consist entirely of directors who meet the definition of “independent” as set forth in the Corporate Governance Standards of the New York Stock Exchange, including the additional independence requirements set forth in New York Stock Exchange Listed Company Manual Section 303A.02(a)(ii). • Members of the Committee will be appointed by the Board each year. • Each Committee member will serve at the pleasure of the Board for such term as the Board may decide or until such Committee member is no longer a Board member. • The Committee shall consist of a minimum of three directors. General Purposes The general purposes of the Committee are to: • Oversee the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers (for purposes of this Charter, “executive officers” means the Company’s Section 16 “officers” as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended); • Assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of executive officer compensation throughout the Company, including benefits and perquisites, and compensation for any other employees designated by the Committee for such purposes; • Discharge similar responsibilities with respect to the compensation of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices. 2 Duties and Responsibilities The Committee will: Executive Compensation and Incentives. • Oversee and maintain a competitive executive officer compensation program in order to attract and retain qualified executives and to provide incentives to executive officers that reward pay for performance in attaining the Company’s goals and objectives. • Review and approve a peer group of companies to be used for marketplace trend analysis and to assess the competitiveness of the Company’s total compensation opportunities for executive officers. • Review and approve corporate goals and objectives relevant to the Chief Executive Officer’s compensation; in conjunction with the evaluation conducted by the Board as described in the Company’s Corporate Governance Guidelines, evaluate the Chief Executive Officer’s performance in light of these goals and objectives; and determine and approve (or determine and approve, and recommend to the independent members of the Board for their determination and approval) the Chief Executive Officer’s compensation level based on this evaluation and comparable market data provided by an independent compensation consultant. • In determining the long-term incentive component of the Chief Executive Officer’s compensation, consider the Company’s performance and relative shareholder return, the value of similar incentive awards to chief executive officers at comparable companies, and the awards given to the Chief Executive Officer in the past. • Review and approve the compensation of other executive officers of the Company, including benefits and perquisites, taking into consideration the Company’s performance, comparable market data, the performance of each executive officer, and such other factors as may, in the Committee’s discretion, be appropriate. • In evaluating and making recommendations regarding, or determining and approving, executive compensation, the Committee shall consider the results of the most recent shareholder advisory vote on executive compensation (“Say on Pay Vote”) required by Section 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). • With respect to incentive compensation plans and equity-based plans: • Make recommendations to the Board with respect to the approval of incentive compensation plans for executive officers and all equity-based plans. • Review and approve equity-based grants and awards, including long-term incentive plan awards, to officers, senior managers, key employees, and other employees of the Company and its subsidiaries under the Company’s equity-based plans. • Review and approve the performance criteria, target awards, payout criteria and like items for the Company’s long-term incentive compensation plans. • Review and approve (a) attainment levels for executive officers under the Company’s annual incentive plan; (b) payments to executive officers under the annual incentive plan; and (c) payments to executive officers under the Company’s long-term incentive compensation plans. • Administer the Company’s equity-based incentive compensation plans and other plans 3 adopted by the Board that contemplate administration by the Committee. • Review and approve special bonuses and/or other awards to executive officers on a case-by- case basis for outstanding performance. • Review and approve the terms of all employment agreements, management continuity agreements and change in control agreements for elected officers.

主要特性 在三个经ISO 13485认证的生产设施生产，在 全球范围内提供质量稳定一致的产品，并增加 供应稳定性 变更控制记录的级别高于CAS编号级别，降低 变更风险 不含动物源性物质和邻苯二甲酸盐 可用作预着色配方或母粒，用于不同的聚合物 • • • • 注册药品管理档案（III类）和/或医疗器械主 文件 食品接触符合FDA/EU**要求 法规支持 原材料根据以下标准检测： - ISO 10993-1和美国药典 生物学 评估 - 欧洲药典3.1.3/3.1.5（聚烯烃） - 美国药典（聚乙烯） - ICH Q3D 杂质元素 • • • * 设计备注：选择效果颜色时需要仔细考虑零件设计和聚合物流动路径， 从而尽可能减少可见流线。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

主要特性 在三个通过ISO 13485认证的医疗生产线生 产全球统一的配方，提供全球一致性和供应 链保障 变更控制记录不限于CAS编号级别，降低变 更风险 • • 不含动物源性物质和邻苯二甲酸盐 可用作各种聚合物的母粒或即用型配方 为方便起见，可在一个产品中实现功能性和颜 色的组合 • • • 法规支持 经过预测试的原材料： - ISO 10993-1 - USP 第、章（VI类） - USP （指南），6.2.3 可萃取元素； USP - ICHQ3D/USP 2 可萃取金属 - 欧洲药典 3.1 聚烯烃（如适用） FDA发布的注册药品主文件（III类）和/或医疗 器械主文件 为符合（新）法规（如IVDR）的批准或过渡提 供文档支持 • • • 适用医疗保健使用限制—见下文。 在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

For and on behalf of BSI: Carlos Pitanga, Chief Operating Officer Assurance – Americas Certification Date: 2018-07-11 Latest Issue: 2018-07-11 Expiry Date: 2021-07-10 BSI Certificate Number: 85585 IATF Number: 0315491 Page: 1 of 2 This certificate remains the property of BSI and shall be returned immediately upon request.

The new accounting standard is effective January 1, 2018 and requires all components of annual periodic pension and postretirement costs, other than service costs, to be presented below Operating Income.

DOCUMENT NUMBER_ SSS-003 CATEGORY DETAIL EC Number 215-175-0 CAS Number 1309-64-4 Name Subclass 1 Antimony Trioxide (ATO) Structural Formula CHEMICAL IDENTITY PROPERTY DETAIL Physical State Solid Form Powder Color White Odor Odorless Melting Point 656°C Boiling Point 1425°C Bulk Density 5.20 g/cm3 Water Solubility Slightly Soluble PHYSICAL/ CHEMICAL PROPERTIES DOCUMENT NUMBER_ SSS-003 HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer It is very unlikely that consumers would be exposed to ATO in its concentrated form because it is only sold for industrial use to make polymers and other products and is not sold directly to consumers.

MYYNTIEHDOT Näitä Myyntiehtoja sovelletaan Avient Corporationin tai sen tytär-/sidosyhtiön (”Myyjä”) toteuttamaan Tuotteiden myyntiin toisille osapuolille (“Ostaja”). 1. Jos Ostaja myy Tuotteet uudelleen, Ostaja hyväksyy Ostajan Avient- tuotteiden jälleenmyyntiä koskevat ehdot, jotka sijaitsevat osoitteessa www.avient.com/terms. Myyntiehdot (1. huhtikuuta 2024)

YELLOW ORANGE T025-1-1 CLPP GREEN T305-1-1 CLPP.CMSE HOT PINK T115-1-1 CLPP.CMSE

NORTH AMERICA (Goods manufactured by Avient): Use the search boxes on the current page to use the online search for SDS for products manufactured by Avient. LIQUID ADDITIVE NUAGE 1 NORTH AMERICA (Goods manufactured by Avient): Use the search boxes on the current page to use the online search for SDS for products manufactured by Avient.